Antiproliferative potential of Artemisia capillaris polysaccharide against human nasopharyngeal carcinoma cells

Guofang Feng(First Affiliated Hospital of Chinese PLA General Hospital), Meikui Zhang(Chinese PLA General Hospital), Xiaohua Cheng(Beijing Tongren Hospital), Changxuan You(Southern Medical University), Xiaoqing Wang(First Affiliated Hospital of Chinese PLA General Hospital), Chengyong Zhou(First Affiliated Hospital of Chinese PLA General Hospital), Zeli Han(First Affiliated Hospital of Chinese PLA General Hospital), Liang Zong(First Affiliated Hospital of Chinese PLA General Hospital)
Carbohydrate Polymers
October 18, 2012
10.1016/j.carbpol.2012.10.024
Cited by 26

Related Papers

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)
|Annals of Oncology|2015|467
TRPM7 regulates the migration of human nasopharyngeal carcinoma cell by mediating Ca2+ influx
|Cell Calcium|2010|135
CCNB2 overexpression is a poor prognostic biomarker in Chinese NSCLC patients
|Biomedicine & Pharmacotherapy|2015|126
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)
|Annals of Oncology|2013|120